Over 2 million Australians have diabetes and up to one in three adults will develop diabetes or pre-diabetes in their lifetime with the associated burden of complications. It is not simply genetics, as the genetic variability cannot explain why some individuals and indeed some families appear to be programmed to have an inordinate burden of complications. Over the last decade we have developed state of the art technologies to characterise epigenetic changes in human clinical cohorts.
Casting The Net: A New Approach To Identify Therapeutics To Treat Type-2 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,068,283.00
Summary
The discovery of treatments for type-2 diabetes (T2D) is a national health priority. In T2D, cells in the brain become 'insulin resistant' resulting in dangerously high blood sugar levels. There are no treatments for brain insulin resistance. The extracellular structures that surround brain cells undergo change in T2D, resulting in insulin resistance. By furthering understanding of these extracellular brain structures, this proposal will identify new drug targets to treat T2D.
Preservation And Generation Of Beta Cells In Type 1 Diabetes With Novel Mimetic Peptides
Funder
National Health and Medical Research Council
Funding Amount
$1,096,055.00
Summary
Type 1 diabetes (T1D) is an autoimmune disease that destroys insulin producing beta cells in the pancreas. It can cause heart and kidney disease, and nerve damage. T1D is treated with insulin injections that can cause life-threatening low blood sugar levels. We have developed a new treatment that may stop beta cell loss, generate new beta cells and remove the need for insulin injections in T1D patients. A positive outcome will identify a completely new T1D treatment option.
Tolerising Antigen-specific Immunotherapy For Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$1,395,549.00
Summary
We have developed a new immunotherapy to treat the underlying causes of type 1 diabetes (T1D) while leaving the rest of the immune system intact. To use this in patients, we need better tests to know when immune therapy is working. We will develop new methods to design the therapy and tools to track the relevant immune cells in T1D that work in variable patient groups. The knowledge gained will speed the pace of development and increase the chance of success of immunotherapy in T1D.